Building business at BIO-Europe
4,000 attendees, 2,100 companies, 60 countries – BIO-Europe, known as Europe’s largest life sciences partnering conference, continues to grow in success. For the first time, CCAB attended the meeting.
- Developing antibody therapeutics and looking to expand their pipeline of immuno-oncology drug candidates,
- Designing CAR-T therapies and requiring antibody sequences against highly-specific tumour antigens, and
- Building antibody drug conjugate (ADC) therapies and interested in CCAB’s antibody portfolio.
Companies developing CAR-T and ADC therapies were particularly interested in potentially working with CCAB because of our capacity to configure multiple binders against different epitopes which provides multiple opportunities to target abnormal cells, like cancer.
From discovery and development to validation and licensing, CCAB reduces the time, risk, and costs associated with bringing new antibodies to market. Want to learn more about partnering with CCAB? Contact us.
Meet CCAB at BIO-Europe 2017
(Originally published October 25)
The CCAB business development team members are on the move again. On the heels of successful participation in BioJapan, James Pan, Vice-President, Product Development, and Ivan Waissbluth, Director, Business Development, will be attending BIO-Europe 2017 in Berlin, Germany, November 6-8.
BIO-Europe is Europe’s largest life science partnering conference, bringing together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled planning meetings and strategic panel discussions. BIO-Europe 2017 is expected to draw over 3,800 industry attendees representing upwards of 2,000 companies from over 60 countries.
Get in touch with us today to arrange a meeting at BIO-Europe. We look forward to seeing you in Berlin.